Limits...
MRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor.

Halon A, Materna V, Donizy P, Matkowski R, Rabczynski J, Lage H, Surowiak P - Arch. Gynecol. Obstet. (2012)

Bottom Line: To determine the prognostic value of the immunohistochemical evaluation of the multidrug resistance-associated protein 2 (MRP2) expression, together with its subcellular localization in primary fallopian tube carcinomas (PFTCs).The immunohistochemical analysis was performed using samples originating from 70 patients with PFTCs. (1) We documented that MRP2 can be localized in the plasma membrane (MRP2c), as well as in the nuclear envelope (MRP2n) of the PFTC cells. (2) Patients with more advanced stage, with progression of the disease and patients who died, showed significantly higher expression of the MRP2n. (3) Univariate and multivariate analyses showed that MRP2n is an unfavorable prognostic factor in PFTCs. (4) The analysis of the classic clinicopathological data revealed that only the FIGO stage had prognostic value, both in the univariate, as well as in multivariate analysis. (1) This study suggests that MRP2n is a new disadvantageous prognostic factor in PFTCs and (2) that expression in nuclear envelope can be associated with lower differentiation of cancer cells and their resistance to the cisplatin. (3) We have also confirmed independent prognostic value of FIGO stage in PFTCs.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, ul. Borowska 213, 50-556 Wroclaw, Poland. ahalon2@gmail.com

ABSTRACT

Objective: To determine the prognostic value of the immunohistochemical evaluation of the multidrug resistance-associated protein 2 (MRP2) expression, together with its subcellular localization in primary fallopian tube carcinomas (PFTCs).

Methods: The immunohistochemical analysis was performed using samples originating from 70 patients with PFTCs.

Results: (1) We documented that MRP2 can be localized in the plasma membrane (MRP2c), as well as in the nuclear envelope (MRP2n) of the PFTC cells. (2) Patients with more advanced stage, with progression of the disease and patients who died, showed significantly higher expression of the MRP2n. (3) Univariate and multivariate analyses showed that MRP2n is an unfavorable prognostic factor in PFTCs. (4) The analysis of the classic clinicopathological data revealed that only the FIGO stage had prognostic value, both in the univariate, as well as in multivariate analysis.

Conclusions: (1) This study suggests that MRP2n is a new disadvantageous prognostic factor in PFTCs and (2) that expression in nuclear envelope can be associated with lower differentiation of cancer cells and their resistance to the cisplatin. (3) We have also confirmed independent prognostic value of FIGO stage in PFTCs.

Show MeSH

Related in: MedlinePlus

Immunohistochemical localization of MRP2 expression in: a normal fallopian tube epithelium, b–d primary fallopian tube carcinomas (hematoxylin, ×400)
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3569580&req=5

Fig1: Immunohistochemical localization of MRP2 expression in: a normal fallopian tube epithelium, b–d primary fallopian tube carcinomas (hematoxylin, ×400)

Mentions: We documented the expression of MRP2 in the normal ovarian epithelium in apical cell membrane of the majority of the cells and in the nuclear envelope in few cases (Fig. 1a). In case of PFTCs, the MRP2-specific staining reactions demonstrated a subcellular localization of MRP2 in the plasma membrane and cytoplasm (MRP2c) (Fig. 1b) as well as in the nuclear envelope (MRP2n) (Fig. 1c) and both localizations (Fig. 1d). The localization and the expression level of MRP2 were heterogenic in individual cases. Mean expression of MRP2c was 1.26 ± 1.77 SD (range 0–8) in the IRS scale and in case of MRP2n mean expression was 4.37 ± 3.65 SD (range 0–12) in the IRS scale. The expression of MRP2 in the nuclear envelope was significantly higher compared to its expression in the plasma membrane (P < 0.001).Fig. 1


MRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor.

Halon A, Materna V, Donizy P, Matkowski R, Rabczynski J, Lage H, Surowiak P - Arch. Gynecol. Obstet. (2012)

Immunohistochemical localization of MRP2 expression in: a normal fallopian tube epithelium, b–d primary fallopian tube carcinomas (hematoxylin, ×400)
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3569580&req=5

Fig1: Immunohistochemical localization of MRP2 expression in: a normal fallopian tube epithelium, b–d primary fallopian tube carcinomas (hematoxylin, ×400)
Mentions: We documented the expression of MRP2 in the normal ovarian epithelium in apical cell membrane of the majority of the cells and in the nuclear envelope in few cases (Fig. 1a). In case of PFTCs, the MRP2-specific staining reactions demonstrated a subcellular localization of MRP2 in the plasma membrane and cytoplasm (MRP2c) (Fig. 1b) as well as in the nuclear envelope (MRP2n) (Fig. 1c) and both localizations (Fig. 1d). The localization and the expression level of MRP2 were heterogenic in individual cases. Mean expression of MRP2c was 1.26 ± 1.77 SD (range 0–8) in the IRS scale and in case of MRP2n mean expression was 4.37 ± 3.65 SD (range 0–12) in the IRS scale. The expression of MRP2 in the nuclear envelope was significantly higher compared to its expression in the plasma membrane (P < 0.001).Fig. 1

Bottom Line: To determine the prognostic value of the immunohistochemical evaluation of the multidrug resistance-associated protein 2 (MRP2) expression, together with its subcellular localization in primary fallopian tube carcinomas (PFTCs).The immunohistochemical analysis was performed using samples originating from 70 patients with PFTCs. (1) We documented that MRP2 can be localized in the plasma membrane (MRP2c), as well as in the nuclear envelope (MRP2n) of the PFTC cells. (2) Patients with more advanced stage, with progression of the disease and patients who died, showed significantly higher expression of the MRP2n. (3) Univariate and multivariate analyses showed that MRP2n is an unfavorable prognostic factor in PFTCs. (4) The analysis of the classic clinicopathological data revealed that only the FIGO stage had prognostic value, both in the univariate, as well as in multivariate analysis. (1) This study suggests that MRP2n is a new disadvantageous prognostic factor in PFTCs and (2) that expression in nuclear envelope can be associated with lower differentiation of cancer cells and their resistance to the cisplatin. (3) We have also confirmed independent prognostic value of FIGO stage in PFTCs.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, ul. Borowska 213, 50-556 Wroclaw, Poland. ahalon2@gmail.com

ABSTRACT

Objective: To determine the prognostic value of the immunohistochemical evaluation of the multidrug resistance-associated protein 2 (MRP2) expression, together with its subcellular localization in primary fallopian tube carcinomas (PFTCs).

Methods: The immunohistochemical analysis was performed using samples originating from 70 patients with PFTCs.

Results: (1) We documented that MRP2 can be localized in the plasma membrane (MRP2c), as well as in the nuclear envelope (MRP2n) of the PFTC cells. (2) Patients with more advanced stage, with progression of the disease and patients who died, showed significantly higher expression of the MRP2n. (3) Univariate and multivariate analyses showed that MRP2n is an unfavorable prognostic factor in PFTCs. (4) The analysis of the classic clinicopathological data revealed that only the FIGO stage had prognostic value, both in the univariate, as well as in multivariate analysis.

Conclusions: (1) This study suggests that MRP2n is a new disadvantageous prognostic factor in PFTCs and (2) that expression in nuclear envelope can be associated with lower differentiation of cancer cells and their resistance to the cisplatin. (3) We have also confirmed independent prognostic value of FIGO stage in PFTCs.

Show MeSH
Related in: MedlinePlus